Literature DB >> 27165692

Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening.

Bjarte Aarmo Lund1, Tony Christopeit1, Yngve Guttormsen2, Annette Bayer2, Hanna-Kirsti S Leiros1.   

Abstract

The spread of antibiotic resistant bacteria is a global threat that shakes the foundations of modern healthcare. β-Lactamases are enzymes that confer resistance to β-lactam antibiotics in bacteria, and there is a critical need for new inhibitors of these enzymes for combination therapy together with an antibiotic. With this in mind, we have screened a library of 490 fragments to identify starting points for the development of new inhibitors of the class D β-lactamase oxacillinase-48 (OXA-48) through surface plasmon resonance (SPR), dose-rate inhibition assays, and X-ray crystallography. Furthermore, we have uncovered structure-activity relationships and used alternate conformations from a crystallographic structure to grow a fragment into a more potent compound with a KD of 50 μM and an IC50 of 18 μM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27165692     DOI: 10.1021/acs.jmedchem.6b00660

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Structure, activity and thermostability investigations of OXA-163, OXA-181 and OXA-245 using biochemical analysis, crystal structures and differential scanning calorimetry analysis.

Authors:  Bjarte Aarmo Lund; Ane Molden Thomassen; Trine Josefine Olsen Carlsen; Hanna Kirsti S Leiros
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2017-10-02       Impact factor: 1.056

2.  Identifying Oxacillinase-48 Carbapenemase Inhibitors Using DNA-Encoded Chemical Libraries.

Authors:  Doris Mia Taylor; Justin Anglin; Suhyeorn Park; Melek N Ucisik; John C Faver; Nicholas Simmons; Zhuang Jin; Murugesan Palaniappan; Pranavanand Nyshadham; Feng Li; James Campbell; Liya Hu; Banumathi Sankaran; B V Venkataram Prasad; Hongbing Huang; Martin M Matzuk; Timothy Palzkill
Journal:  ACS Infect Dis       Date:  2020-03-25       Impact factor: 5.084

3.  Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.

Authors:  Yong Ai; Lucia Hwang; Alexander D MacKerell; Ari Melnick; Fengtian Xue
Journal:  J Med Chem       Date:  2021-04-12       Impact factor: 7.446

4.  OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs.

Authors:  Christopher Fröhlich; Vidar Sørum; Ane Molden Thomassen; Pål Jarle Johnsen; Hanna-Kirsti S Leiros; Ørjan Samuelsen
Journal:  mSphere       Date:  2019-03-27       Impact factor: 4.389

5.  Cryptic β-Lactamase Evolution Is Driven by Low β-Lactam Concentrations.

Authors:  Ørjan Samuelsen; Christopher Fröhlich; João A Gama; Klaus Harms; Viivi H A Hirvonen; Bjarte A Lund; Marc W van der Kamp; Pål J Johnsen; Hanna-Kirsti S Leiros
Journal:  mSphere       Date:  2021-04-28       Impact factor: 4.389

6.  Discovery of Novel Chemical Series of OXA-48 β-Lactamase Inhibitors by High-Throughput Screening.

Authors:  Barbara Garofalo; Federica Prati; Rosa Buonfiglio; Isabella Coletta; Noemi D'Atanasio; Angela Molteni; Daniele Carettoni; Valeria Wanke; Giorgio Pochetti; Roberta Montanari; Davide Capelli; Claudio Milanese; Francesco Paolo Di Giorgio; Rosella Ombrato
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-25

7.  Biochemical and biophysical characterization of the OXA-48-like carbapenemase OXA-436.

Authors:  Bjarte Aarmo Lund; Ane Molden Thomassen; Trine Josefine Warg Carlsen; Hanna Kirsti Schrøder Leiros
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2021-08-31       Impact factor: 1.056

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.